MAP7 and ovarian cancer: A deeper dive into the association between MAP7 expression and clinicopathological traits among 98 ovarian cancer patients disclosed a significant correlation with patient age and FIGO stage (Fig. 1G), revealing elevated expression in older individuals and advanced disease stages (Table 1).